Eli Lilly & Co. (LLY), Incyte Corporation (INCY) Report Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis

February 4, 2019 6:46 AM
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Next Articles